Ether

Ether

SCHEMBL5358570

CCN1c2ncc(CCOc3ccnc4ccccc34)cc2C(=O)N(C)c2cccnc21.CCOCC

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.61
CYP2C9 P11712 3/20 0.61
CYP2C19 P33261 3/20 0.61
CYP1A2 P05177 1/20 0.46
BRD4 O60885 6/20 0.38
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
PDE10A Q9Y233 4/20 0.33
HTR1A P08908 2/20 0.32
ALDH1A1 P00352 1/20 0.32
NCF1 P14598 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5244757 0.97 CYP3A4 (0.65) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
Hydrochloric Acid SCHEMBL5243727 0.96 CYP3A4 (0.64) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL14383886 0.92 CYP2C9 (0.66) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL5782914 0.90 CYP3A4 (0.55) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL5742832 0.86 CYP2C9 (0.54) CYP3A4CYP2C9CYP2C19CYP1A2KMT2A
SCHEMBL5745565 0.85 CYP2C9 (0.52) CYP3A4CYP2C9CYP2C19CYP1A2PDE10A
SCHEMBL5744780 0.85 CYP2C9 (0.64) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL5316250 0.85 CYP2C9 (0.66) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL5779285 0.83 CYP3A4 (0.52) CYP3A4CYP2C9CYP2C19CYP1A2HTR1A
SCHEMBL14290762 0.83 CYP3A4 (0.65) CYP3A4CYP2C9CYP2C19CYP1A2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7309700-B2 Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2′,3′-e] [1,4]diazepin-6-one BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-18 US disclosed
US-20050222134-A1 Crystalline forms of 5, 11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222134-A1 Crystalline forms of 5, 11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one CYP4B1, AQP4, DDO CYP3A4 58/4885CYP2C9 322/4885CYP2C19 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.